Observational studyHuman vaccines & immunotherapeutics2023
Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021.
Francesca Fortunato et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.